Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea40
record_format dspace
spelling oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea402021-12-02T06:30:52ZSingle- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]1179-1438https://doaj.org/article/0e4dedde10cd43628941128f1a86ea402014-03-01T00:00:00Zhttp://www.dovepress.com/single--and-multiple-dose-pharmacokinetics-pharmacodyncorrigendum-a16243https://doaj.org/toc/1179-1438 Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original articleCui YSong YWang JYu ZSchuster ABarrett YCFrost CDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 61-62 (2014)
institution DOAJ
collection DOAJ
language EN
topic Therapeutics. Pharmacology
RM1-950
spellingShingle Therapeutics. Pharmacology
RM1-950
Cui Y
Song Y
Wang J
Yu Z
Schuster A
Barrett YC
Frost C
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
description Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original article
format article
author Cui Y
Song Y
Wang J
Yu Z
Schuster A
Barrett YC
Frost C
author_facet Cui Y
Song Y
Wang J
Yu Z
Schuster A
Barrett YC
Frost C
author_sort Cui Y
title Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_short Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_full Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_fullStr Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_full_unstemmed Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_sort single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy chinese subjects [corrigendum]
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40
work_keys_str_mv AT cuiy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT songy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT wangj singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT yuz singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT schustera singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT barrettyc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
AT frostc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
_version_ 1718399857549377536